BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 24166743)

  • 21. The complexity of intestinal absorption and exsorption of digoxin in rats.
    Yao HM; Chiou WL
    Int J Pharm; 2006 Sep; 322(1-2):79-86. PubMed ID: 16781832
    [TBL] [Abstract][Full Text] [Related]  

  • 22. P-glycoprotein: a focus on characterizing variability in cardiovascular pharmacotherapeutics.
    Al-Khazaali A; Arora R
    Am J Ther; 2014; 21(1):2-9. PubMed ID: 24401702
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Kinetic profiling of P-glycoprotein-mediated drug efflux in rat and human intestinal epithelia.
    Stephens RH; O'Neill CA; Warhurst A; Carlson GL; Rowland M; Warhurst G
    J Pharmacol Exp Ther; 2001 Feb; 296(2):584-91. PubMed ID: 11160647
    [TBL] [Abstract][Full Text] [Related]  

  • 24. In vitro to in vivo evidence of the inhibitor characteristics of Schisandra lignans toward P-glycoprotein.
    Liang Y; Zhou Y; Zhang J; Liu Y; Guan T; Wang Y; Xing L; Rao T; Zhou L; Hao K; Xie L; Wang GJ
    Phytomedicine; 2013 Aug; 20(11):1030-8. PubMed ID: 23731657
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Rifampin's acute inhibitory and chronic inductive drug interactions: experimental and model-based approaches to drug-drug interaction trial design.
    Reitman ML; Chu X; Cai X; Yabut J; Venkatasubramanian R; Zajic S; Stone JA; Ding Y; Witter R; Gibson C; Roupe K; Evers R; Wagner JA; Stoch A
    Clin Pharmacol Ther; 2011 Feb; 89(2):234-42. PubMed ID: 21191377
    [TBL] [Abstract][Full Text] [Related]  

  • 26. P-glycoprotein mediated efflux in Caco-2 cell monolayers: the influence of herbals on digoxin transport.
    Oga EF; Sekine S; Shitara Y; Horie T
    J Ethnopharmacol; 2012 Dec; 144(3):612-7. PubMed ID: 23064285
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Echinacea purpurea and P-glycoprotein drug transport in Caco-2 cells.
    Hansen TS; Nilsen OG
    Phytother Res; 2009 Jan; 23(1):86-91. PubMed ID: 18688789
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clarification of P-glycoprotein inhibition-related drug-drug interaction risks based on a literature search of the clinical information.
    Umeyama Y; Fujioka Y; Okuda T
    Xenobiotica; 2014 Dec; 44(12):1135-44. PubMed ID: 24937160
    [TBL] [Abstract][Full Text] [Related]  

  • 29. 1Alpha,25-dihydroxyvitamin D3 up-regulates P-glycoprotein via the vitamin D receptor and not farnesoid X receptor in both fxr(-/-) and fxr(+/+) mice and increased renal and brain efflux of digoxin in mice in vivo.
    Chow EC; Durk MR; Cummins CL; Pang KS
    J Pharmacol Exp Ther; 2011 Jun; 337(3):846-59. PubMed ID: 21421739
    [TBL] [Abstract][Full Text] [Related]  

  • 30. P-Glycoprotein- and cytochrome P-450-mediated herbal drug interactions.
    Kumar YS; Adukondalu D; Sathish D; Vishnu YV; Ramesh G; Latha AB; Reddy PC; Sarangapani M; Rao YM
    Drug Metabol Drug Interact; 2010; 25(1-4):3-16. PubMed ID: 21417789
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Association between the number of coadministered P-glycoprotein inhibitors and serum digoxin levels in patients on therapeutic drug monitoring.
    Englund G; Hallberg P; Artursson P; Michaëlsson K; Melhus H
    BMC Med; 2004 Apr; 2():8. PubMed ID: 15061868
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The kidney--the body's playground for drugs: an overview of renal drug handling with selected clinical correlates.
    Perri D; Ito S; Rowsell V; Shear NH
    Can J Clin Pharmacol; 2003; 10(1):17-23. PubMed ID: 12687033
    [TBL] [Abstract][Full Text] [Related]  

  • 33. OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine.
    Cvetkovic M; Leake B; Fromm MF; Wilkinson GR; Kim RB
    Drug Metab Dispos; 1999 Aug; 27(8):866-71. PubMed ID: 10421612
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Drug-Drug Interactions of P-gp Substrates Unrelated to CYP Metabolism.
    Akamine Y; Yasui-Furukori N; Uno T
    Curr Drug Metab; 2019; 20(2):124-129. PubMed ID: 30280663
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin.
    Greiner B; Eichelbaum M; Fritz P; Kreichgauer HP; von Richter O; Zundler J; Kroemer HK
    J Clin Invest; 1999 Jul; 104(2):147-53. PubMed ID: 10411543
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Caco-2 cell methodology and inhibition of the P-glycoprotein transport of digoxin by Aloe vera juice.
    Djuv A; Nilsen OG
    Phytother Res; 2008 Dec; 22(12):1623-8. PubMed ID: 19003953
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Characterization of digoxin uptake in sandwich-cultured human hepatocytes.
    Kimoto E; Chupka J; Xiao Y; Bi YA; Duignan DB
    Drug Metab Dispos; 2011 Jan; 39(1):47-53. PubMed ID: 20926619
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of interferon-gamma on the pharmacokinetics of digoxin, a P-glycoprotein substrate, intravenously injected into the mouse.
    Kawaguchi H; Matsui Y; Watanabe Y; Takakura Y
    J Pharmacol Exp Ther; 2004 Jan; 308(1):91-6. PubMed ID: 14569074
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacokinetic and pharmacodynamic drug interactions with new oral anticoagulants: what do they mean for patients with atrial fibrillation?
    Hellwig T; Gulseth M
    Ann Pharmacother; 2013 Nov; 47(11):1478-87. PubMed ID: 24259602
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A review on the impact of P-glycoprotein on the penetration of drugs into the brain. Focus on psychotropic drugs.
    Linnet K; Ejsing TB
    Eur Neuropsychopharmacol; 2008 Mar; 18(3):157-69. PubMed ID: 17683917
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.